ACI Webinars

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Advances in Cancer Immunotherapy: A Focus on Nurses

Enduring Materials Available

Organizers

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, FAAN
Smilow Cancer Hospital, Yale Cancer Center, Yale School of Nursing

Beth Sandy, MSN, CRNP
Abramson Cancer Center, University of Pennsylvania

View Enduring Materials

Program Description

The ACI Nurses program is a CME certified course geared specifically for nurses using cancer immunotherapy in a clinical setting. This program will prepare you to better treat cancer patients using immunotherapy.

Program Agenda

The Expanding Landscape of Immune Checkpoint Inhibitor Therapy:  What Nurses Need to Know
Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, FAAN

Preparing Patients for Immune Checkpoint Inhibitor Therapy
Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, FAAN

irAE's: How Nurses can Differentiate and Manage
Beth Sandy, MSN, CRNP

Question & Answer

Concluding remarks

Learning Objectives

  1. Describe the mechanisms of immune-related adverse reactions from cancer immunotherapy treatment.
  2. Identify and properly triage immune-related adverse events related to cancer immunotherapy.
  3. Identify available patient education resources for cancer immunotherapy immune-related adverse events.

Advances in Cancer Immunotherapy: A Focus on Community Clinicians

Enduring Materials Available

Organizers

Sigrun Hallmeyer, MD
Advocate Health Care

Raju Vaddepally, MD
Yuma Regional Medical Center

Enduring Materials

Program Description

The ACI Community Clinician program is a CME certified course geared specifically for community clinicians using cancer immunotherapy in a clinical setting. This program will prepare you to better treat cancer patients using immunotherapy.

Program Handout

Program Agenda

11:05 p.m. CDT

Welcome 

1:05–1:25 p.m. CDT

Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections
Sandip Patel, MD

1:25–1:40 p.m. CDT

ES-SCLC: Changing Paradigms with Immuno-Oncology Combinations
Sandip Patel, MD

1:40–2:00 p.m. CDT

CAR-T Therapy for Hematologic Malignancies and Solid Tumors
Natalie Callander, MD

2:00–2:15 p.m. CDT

Toxicities Associated with CAR-T Therapy
Natalie Callander, MD

2:15–2:25 p.m. CDT

Question & Answer Session

2:25 p.m. CDT

Concluding remarks

Learning Objectives

  1. Describe the mechanisms of immune-related adverse reactions from cancer immunotherapy treatment.
  2. Identify and properly triage immune-related adverse events related to cancer immunotherapy.
  3. Identify available patient education resources for cancer immunotherapy immune-related adverse events.

Advances in Cancer Immunotherapy: A Focus on Emergency Physicians

Enduring Materials Coming Soon!

Organizers

Paul Jansson, MD, MS
Brigham and Women's Hospital

Alexa Meara, MD
The Ohio State Wexner Medical Center

Program Description

The ACI: A Focus on Emergency Physicians program is a CME certified course geared specifically for emergency physicians  to better treat cancer patients receiving immunotherapy.

Program Agenda

1:00–1:05 p.m. EDT

Welcome 

1:05–1:25 p.m. EDT

Basics of Immuno-Oncology in the Emergency Department
Paul Jansson, MD, MS

1:25–1:40 p.m. EDT

Emergency Department Diagnosis and Management of irAEs
Jason Bischof, MD

1:40–1:50 p.m. EDT

Case Studies in Emergency Department Care Delivery
Alexa Meara, MD

1:50–2:00 p.m. EDT

Question & Answer Session

2:00 p.m. EDT

Concluding remarks

Learning Objectives

  1. Describe the basic principles of cancer immunotherapy.
  2. Describe the mechanisms of immune-related adverse reactions from cancer immunotherapy treatment.
  3. Identify and properly triage immune-related adverse events related to cancer immunotherapy.

Advances in Cancer Immunotherapy: A Focus on Pharmacists

Enduring Materials Coming Soon!

Organizers

Suzanne Jones, PharmD
Sarah Cannon Research Institute

Eve Segal, PharmD, BCOP
Seattle Cancer Care Alliance

Program Description

The ACI: A Focus on Pharmacists program is a CME certified course geared specifically for pharmacists using cancer immunotherapy in a clinical setting. This program will prepare you to better treat cancer patients using immunotherapy.

Program Agenda

1:001:05 p.m. CDT

Welcome 

1:05–1:20p.m. CDT

Emerging Drug-Drug Interactions with Immunotherapy

Eve Segal, PharmD, BCOP

Evan Hall, MD, MPhil

1:20–1:30 p.m. CDT

Discussion / Question & Answer

1:30–1:45 p.m. CDT

A Growing Repertoire: Expanding Role of CAR-T and Bispecific Antibodies

Grace Baek, PharmD, BCOP

1:45–2:00 p.m. CDT

Discussion / Question & Answer

2:00 p.m. CDT

Concluding remarks

Learning Objectives

  1. Identify adverse drug-drug reactions in cancer immunotherapy.
  2. Describe the mechanisms of action for cellular therapies and bispecifics in clinical application.
  3. Discuss the use of immunotherapy treatments in an outpatient setting.

Accreditation Information

Joint Accreditation Statement 

 


In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Pharmacy Continuing Education

PACE designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. 

 

For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.  

Advances in Cancer Immunotherapy: A Focus on Advanced Practitioners

Monday, Nov. 13, 2023  |  5-6:30 p.m. EST  |  Virtual (Zoom)

Organizers

Krista Rubin, MS, FNP-BC
Massachusetts General Hospital

Program Description

The ACI: A Focus on Advanced Practitioners program is a CME certified course geared specifically for advanced practitioners using cancer immunotherapy in a clinical setting. This program will prepare you to better treat cancer patients using immunotherapy.

Program Agenda

5–5:05 p.m. EST

Welcome 

5:05–5:15 p.m. EST

Introduction to Immunotherapy

Krista Rubin, MS, FNP-BC

5:15–5:45 p.m. EST

Immunotherapies for Genitourinary Cancers

Erika Meneely, NP and Kara Olivier, NP

5:45–6:00 p.m. EST

Immunotherapy for Melanoma

Lisa Kottschade, APRN, CNP

6:00–6:25 p.m. EST

Faculty Case Study Discussion and Q&A

6:25–6:30 p.m. EST

Concluding remarks

Learning Objectives

  1. Describe the history of cancer immunotherapy.
  2. Identify current and upcoming agents for immunotherapy for solid tumors.
  3. Describe the mechanisms of immune-related adverse events related to cancer immunotherapy treatment.

Accreditation Information

Joint Accreditation Statement

 


In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Education

PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.